Remedy Robotics

AI-powered endovascular robotic systems for remote and autonomous cardiovascular and neurovascular procedures.

Website: https://www.remedyrobotics.com/

Cover Block

From the public record

Field Value
Name Remedy Robotics
Tagline AI-powered endovascular robotic systems for remote and autonomous cardiovascular and neurovascular procedures.
Headquarters San Francisco, United States [Crunchbase, retrieved 2026]
Founded 2020 [Crunchbase, retrieved 2026]
Stage Series B [PR Newswire, November 2026]
Business model Hardware + Software
Industry Healthtech
Technology Robotics
Geography Global / Remote-First
Growth profile Venture Scale
Founding team Co-Founders (2) [Crunchbase, retrieved 2026]
Funding label $50M+
Total disclosed funding ~$62,000,000 [PR Newswire, November 2026]

Links

From the public record

The Short Version

PUBLIC Remedy Robotics is building endovascular surgical robotics for stroke and other vascular procedures, and it merits investor attention now because it disclosed a $62 million Series B in November 2026 to fund a pivotal clinical trial and progress toward FDA approval [PR Newswire, November 2026] [Finsmes, November 2026]. Founded in 2020 and based in San Francisco, the company is focused on a hard clinical access problem: extending specialist intervention beyond the hospitals that have on-site neurointerventional expertise, with its public materials framing the near-term wedge as remote stroke care [Crunchbase, retrieved 2026] [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026].

The product is the N1 System, which the company describes as an AI-enabled platform for neurovascular, coronary, and peripheral vascular procedures, with intended use cases spanning on-site, remote, and eventually autonomous operation; the differentiation, as presented publicly, rests less on generic AI claims than on teleoperation, catheter control, and 3D visualization inside a regulated clinical workflow [PR Newswire, November 2026] [Finsmes, November 2026] [Remedy Robotics, retrieved 2026]. Remedy also says it completed remote neurointerventional procedures in Toronto in October 2025, a notable technical and clinical signal, although the underlying evidence remains limited to company and follow-on coverage rather than a cited peer-reviewed clinical publication in the materials reviewed here [Remedy Robotics, October 2025] [Overnight Success, October 2025] [Global Startups Insights].

Leadership is concentrated in two co-founders. Public coverage identifies Dr. David Bell as co-founder and CEO leading commercial and clinical programs, and Jake Sganga as co-founder and CTO leading hardware, software, machine learning, and autonomy; available sourcing suggests Sganga brings directly relevant robotics training, including a Stanford bioengineering PhD path tied to flexible surgical-device control [Startup Daily, retrieved 2026] [Finsmes, November 2026] [RocketReach, retrieved 2026] [Stanford Bio-X, retrieved 2026].

On capital formation, the picture is clearer than on operating scale. Remedy has disclosed roughly $62 million in total funding through the November 2026 Series B led by DCVC, with participation from UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, and KdT Ventures, and its business model appears to be a hardware plus software sale into hospitals and clinical networks rather than a pure software deployment [PR Newswire, November 2026] [HIT Consultant, November 2026] [Crunchbase, retrieved 2026].

The next 12 to 18 months will turn on regulatory and clinical proof rather than narrative momentum. Investors should watch for pivotal trial execution, evidence of FDA pathway progress, any independent validation of the reported hospital collaborations and remote procedure claims, and signs that a roughly 20-person organization can add the regulatory, manufacturing, and autonomy talent implied by seven open roles posted in November 2026 [Securities.io, November 2026] [LeadIQ, July 2026] [Remedy Robotics, November 2026] [HIT Consultant, November 2026].

Unconfirmed -- Core funding facts are corroborated by multiple public sources, but several material operating and product claims in this section rely on company statements or follow-on coverage repeating company statements.

Taxonomy Snapshot

Axis Value
Stage Series B
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Robotics
Geography Global / Remote-First
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding $50M+ (total disclosed approximately $62,000,000)

The Company in Brief

PUBLIC

The basic outline is clear enough even if the company is still early by public-record standards. Remedy Robotics is a San Francisco-based healthtech company founded in 2020, according to its Crunchbase profile, and its website describes the business in plain terms as building AI-powered endovascular intervention systems for cardiovascular care [Crunchbase] [Remedy Robotics, retrieved 2026].

The public materials center the company on a single flagship platform rather than a broad product catalog. On its website, Remedy Robotics says the N1 System is designed to support physician control, 3D visualization, teleoperation, and automation for endovascular procedures, which is consistent with Crunchbase's positioning of the company as a robotics-focused medical technology startup [Remedy Robotics, retrieved 2026] [Crunchbase].

The visible milestones are recent and mostly financing-linked. Crunchbase lists the company as founded in 2020, while the company website presents the N1 System as its core platform and current operating focus; beyond that, the clearest dated milestone in the public record captured here is the company's November 2026 Series B financing, which appears on Crunchbase alongside investor information and aligns with the company's own public-facing description of its stage of development [Crunchbase] [Remedy Robotics, retrieved 2026].

Single-source, plausible -- Founded year and headquarters are supported by Crunchbase, while product scope relies primarily on the company website.

What They Have Built

MIXED

The product story is concrete enough to analyze, even if much of the detail still comes from the company and financing coverage rather than clinical publications. Remedy Robotics is building the N1 System, described as an AI-enabled robotic platform for neurovascular, coronary, and peripheral vascular procedures, with an immediate focus on remote endovascular stroke care [PR Newswire, November 2026]. Public materials say the system is intended for on-site, remote, or autonomous procedures, and that it gives physicians tool control, 3D visualization, teleoperation, and automation capabilities [Finsmes, November 2026] [Remedy Robotics, retrieved 2026].

The strongest public proof point is not full regulatory clearance, but reported real-world use. Remedy Robotics said it completed the world's first remote neurointerventional procedures using the N1 System in October 2025, and separate coverage reported procedures in Toronto where surgeons remotely controlled robotic catheters [Remedy Robotics, October 2025] [Overnight Success, October 2025]. Another source reported that the procedures at St. Michael's Hospital in Toronto were performed robotically without a bedside interventionist, which, if borne out in broader evidence, would mark a meaningful step beyond standard assistive robotics toward true remote intervention [Global Startups Insights, retrieved 2026]. The current financing is reported to support advancement of the N1 System toward FDA approval and a planned pivotal clinical trial, which suggests the platform remains pre-approval rather than broadly commercial in the U.S. [Securities.io, November 2026] [PR Newswire, November 2026].

The technical footprint implied by hiring is also consistent with a vertically integrated robotics stack, though this part should be treated as inference rather than disclosed architecture. Open roles in autonomy, DevOps, mechanical engineering, manufacturing, quality, and regulatory affairs point to work across robot design, software infrastructure, deployment, and medical-device compliance (inferred from job postings) [Remedy Robotics, November 2026]. For investors, that matters because the company is not presenting as a pure software layer on top of third-party hardware. It appears to be carrying the harder burden, and potentially the defensible one, of integrating robotics, controls, visualization, and clinical workflow into a regulated endovascular system [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026].

Unconfirmed -- Core product descriptions and milestone claims rely heavily on company materials and republished funding coverage, with partial corroboration from third-party press and job postings.

Market Size and Demand

PUBLIC

The market matters now because Remedy Robotics is aiming at a stubborn access bottleneck in stroke and endovascular care, and the public evidence points to timing, staffing, and regulatory progress as the variables that will determine whether remote intervention moves from technical demonstration to hospital budget line [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026].

Public sources do not provide a cited third-party TAM, SAM, or SOM for Remedy Robotics specifically, so the market case has to be framed through the problem the company says it is addressing rather than a precise revenue pool. Remedy states that fewer than 3% of eligible stroke patients worldwide can access endovascular intervention in time, a claim that is material to the access thesis but remains company-sourced in the captured research [Remedy Robotics, retrieved 2026]. The more defensible public read is narrower: if remote endovascular robotics can extend specialist coverage across hospitals that lack on-site neurointerventional capability, the addressable wedge is not all surgical robotics, but the subset of time-sensitive vascular procedures where geography and clinician availability constrain care delivery [PR Newswire, November 2026] [Finsmes, November 2026].

Demand drivers are reasonably clear from the financing and deployment narrative. Remedy says the N1 System is being developed for neurovascular, coronary, and peripheral vascular procedures, with an immediate focus on remote endovascular stroke care [PR Newswire, November 2026] [Finsmes, November 2026]. That matters because stroke intervention is unusually sensitive to delay, and the company has aligned its product positioning around on-site, remote, or autonomous workflows rather than a single in-room robotics use case [Finsmes, November 2026] [Remedy Robotics, retrieved 2026]. The company also says it collaborates with more than 100 hospitals worldwide, which, if directionally accurate, suggests health systems are at least willing to evaluate this operating model before FDA clearance is complete [HIT Consultant, November 2026].

Adjacent markets broaden the opportunity, but they also complicate adoption. Remedy is presenting the N1 System as a platform across neurovascular, coronary, and peripheral vascular intervention, which puts it near several established hospital spending buckets: interventional stroke care, cath lab tooling, vascular surgery infrastructure, and surgical robotics capital equipment [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026]. The substitute path for many hospitals is not another robot, but continued use of conventional catheter-based intervention with local staffing, patient transfer networks, or specialist travel coverage. That makes the economic comparison as much about care access and workflow redesign as device performance.

Regulation and macro conditions sit at the center of the timeline. Remedy's November 2026 financing is explicitly tied to a planned pivotal clinical trial, prototype deployments, autonomous software development, and progress toward FDA approval, which indicates the company is still in a pre-approval value inflection rather than broad commercial scale [PR Newswire, November 2026] [Securities.io, November 2026]. The company also describes teleoperation and automation as part of the product roadmap, and those features could draw a higher evidence burden from regulators and hospital buyers than a conventional assistive device would [Remedy Robotics, retrieved 2026]. In practical terms, market expansion here is likely gated less by theoretical procedure volume than by clinical validation, reimbursement clarity, liability allocation, and hospital comfort with operating without a bedside interventionist in specific settings [Global Startups Insights, retrieved 2026].

Market signal Public claim Source
Access constraint Fewer than 3% of eligible stroke patients worldwide can access endovascular intervention in time [Remedy Robotics, retrieved 2026]
Product scope Neurovascular, coronary, and peripheral vascular procedures [PR Newswire, November 2026]
Care model scope On-site, remote, or autonomous procedures [Finsmes, November 2026]
Early network signal More than 100 hospital collaborations worldwide [HIT Consultant, November 2026]

The table shows why the market can attract investor attention even without a clean third-party sizing model in the record. The strongest public signal is the care access problem; the weakest is still independent validation of how large the deployable hospital opportunity becomes before regulatory clearance.

Unconfirmed -- This section relies materially on company-sourced market framing and product-positioning claims, with partial corroboration from PR Newswire, Finsmes, and HIT Consultant.

Who Else Is Fighting for This

Competitive positioning

MIXED Remedy Robotics is positioning itself against a broad set of alternatives rather than a clearly disclosed list of direct startup peers, with the company’s public wedge centered on remote endovascular intervention and, over time, autonomous cardiovascular and neurovascular procedures [PR Newswire, November 2026] [Finsmes, November 2026].

The competitive map starts with the incumbent standard of care, hospitals performing endovascular procedures with on-site specialist teams and conventional cath lab workflows. Remedy is not claiming to replace the underlying procedure category; it is trying to change where the operator sits and how much of the workflow can be robotic or automated, beginning with stroke-related intervention where specialist scarcity is a binding constraint according to the company’s own framing [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026]. Adjacent substitutes include patient transfer networks and hub-and-spoke stroke systems, which solve access with logistics rather than robotics, and which remain the practical benchmark because they are already embedded in hospital operations.

Among challengers, the public record here is thinner than investors would usually want. The source set does not name direct startup competitors, so the most defensible read is category-based: Remedy sits in surgical robotics, telestroke infrastructure, and endovascular workflow modernization at once, which is strategically interesting but makes apples-to-apples comparison difficult from public evidence alone [Crunchbase, retrieved 2026] [PitchBook, retrieved 2026]. That cuts both ways. It may indicate whitespace around remote neurointervention, but it also means the company’s competitive claims rest heavily on self-described technical firsts and partner relationships that are only partially corroborated in independent coverage [HIT Consultant, November 2026] [citybiz, retrieved 2026].

The clearest edge visible today is problem selection and technical ambition, not yet installed-base control. Remedy says the N1 System can support on-site, remote, or autonomous procedures, and independent coverage repeats that positioning, which gives the company a wider product surface than a single-purpose robotic tool would have if those capabilities translate into clinical and regulatory progress [Finsmes, November 2026] [Remedy Robotics, retrieved 2026]. The reported completion of remote neurointerventional procedures in Toronto in October 2025 is the strongest public signal that the system has moved beyond concept, especially because outside coverage states surgeons remotely controlled robotic catheters and that procedures were carried out without a bedside interventionist at St. Michael’s Hospital [Overnight Success, October 2025] [Global Startups Insights]. Still, durability is not established. Procedure-first advantage in medtech is perishable unless it compounds into regulatory clearance, reference sites, clinician training, and procurement momentum.

The company is also trying to build a moat through networks and capital. Public coverage says Remedy collaborates with more than 100 hospitals worldwide and is planning a pivotal clinical trial with the University of California network, while its November 2026 Series B brought in DCVC alongside investors including UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital, and KdT Ventures [HIT Consultant, November 2026] [PR Newswire, November 2026]. That combination matters because robotics in regulated care usually requires time, specialized talent, and sustained financing. Even so, the hospital collaboration figure is company-linked and not independently unpacked, so it should not yet be read as commercial lock-in or recurring deployment scale [HIT Consultant, November 2026].

Exposure is easier to identify than direct rivalry by name. The company appears most vulnerable to entrenched hospital behavior and regulatory sequencing. A transfer-based stroke network, or any incumbent care pathway that moves the patient rather than the operator, retains the advantage of being reimbursed, understood, and already staffed. Remedy’s own financing announcement says the latest round will support advancement toward FDA approval, which implies the core commercial race is still ahead rather than won [Securities.io, November 2026]. A second exposure is channel ownership. Hospitals, health systems, and clinical networks may collaborate with novel robotics companies, but purchasing committees often prefer proven workflows until pivotal data and clearance reduce perceived clinical and liability risk [PR Newswire, November 2026] [HIT Consultant, November 2026].

The most plausible 18-month scenario is a split between technical validation and commercial proof. Winner if X: Remedy Robotics, if the planned pivotal trial converts the Toronto-style remote procedure narrative into regulator-grade evidence and early health-system references, because that would turn a category story into a procurement story [PR Newswire, November 2026] [Overnight Success, October 2025]. Loser if Y: the status quo transfer-and-hub model, if remote intervention can be shown to improve time-to-treatment without adding unacceptable operational complexity. The inverse also holds. If regulatory timelines slip or remote workflows still require too much local specialist support, the likely loser is Remedy’s autonomy-forward thesis rather than endovascular care itself, because hospitals can continue using existing referral networks while waiting for clearer evidence [Finsmes, November 2026] [Securities.io, November 2026].

Opportunity

Upside case

PUBLIC The prize here is unusually large for a company of this size: if remote endovascular robotics moves from a clinical demonstration to a regulated care pathway, Remedy Robotics could become core infrastructure for how stroke and other vascular interventions are delivered across hospitals that do not have continuous on-site specialist coverage [PR Newswire, November 2026] [Finsmes, November 2026].

The headline opportunity is not simply selling another surgical robot. It is building the operating layer for remote endovascular care, starting with stroke, where time-to-treatment is clinically decisive and access appears constrained enough to create a real adoption wedge. Remedy says the N1 System is built for neurovascular, coronary, and peripheral vascular procedures, and that it supports on-site, remote, or autonomous use cases [PR Newswire, November 2026] [Finsmes, November 2026]. The same public materials tie the current raise to a planned pivotal clinical trial and progress toward FDA approval, which is the right sequence for a company trying to convert technical feasibility into a reimbursable and repeatable hospital workflow [PR Newswire, November 2026] [Securities.io, November 2026].

The reachable part of that upside rests on a narrow but meaningful set of public signals. The company has disclosed a $62 million Series B led by DCVC, with participation from institutional and strategic backers including UC Investments, Skip Capital, Hostplus, Build Collective by Tony Fadell, Blackbird, Divergent Capital, and KdT Ventures [PR Newswire, November 2026] [Finsmes, November 2026]. It also says it collaborates with more than 100 hospitals worldwide, and public coverage describes a 2025 remote neurointerventional milestone in Toronto using the N1 System [HIT Consultant, November 2026] [Overnight Success, October 2025]. Those claims still need more independent clinical validation than is visible in the current record, but they are enough to suggest the company is aiming at a delivery model with network characteristics rather than a one-site capital equipment sale.

Scenario What happens Catalyst Why it's plausible
Remote stroke hub standard Remedy becomes the preferred robotic layer for health systems that want neurointerventional specialists to cover multiple hospitals from a distance A successful pivotal clinical trial in the University of California network, followed by FDA progress for the N1 System [PR Newswire, November 2026] The company is explicitly raising capital for a pivotal trial and FDA path, and its stated focus is remote endovascular stroke care where access constraints are acute [PR Newswire, November 2026] [Remedy Robotics, retrieved 2026]
Hospital network expansion Initial neurovascular deployments lead to broader rollout across coronary and peripheral vascular procedures within the same institutions Proof that the same platform can support multiple endovascular use cases on-site and remotely [PR Newswire, November 2026] [Finsmes, November 2026] Public materials describe one platform spanning neurovascular, coronary, and peripheral procedures, which creates a plausible land-and-expand motion if clinical performance holds [PR Newswire, November 2026]
Automation-led category leader Remedy moves from teleoperation into higher-autonomy workflows and becomes a reference platform for AI-assisted endovascular intervention Clinical and regulatory acceptance of automation features layered onto teleoperation and 3D visualization [Remedy Robotics, retrieved 2026] [Finsmes, November 2026] The N1 System is described as including teleoperation and automation capabilities, and the company positions autonomy as part of the long-term product path rather than a separate program [Remedy Robotics, retrieved 2026] [Finsmes, November 2026]

Compounding, if it shows up, would likely come from workflow depth rather than consumer-style network effects. Each successful deployment can add three things at once: more clinical familiarity for physicians, more procedural data for product refinement, and more institutional trust for the next hospital conversation. Remedy's public positioning already hints at that loop. The company says it collaborates with more than 100 hospitals worldwide, its careers page shows active hiring across autonomy, DevOps, manufacturing, quality, and regulatory affairs, and its platform is framed as teleoperation plus automation rather than a fixed-function device [HIT Consultant, November 2026] [Remedy Robotics, November 2026] [Remedy Robotics, retrieved 2026]. If true, that creates the outline of a compounding system in which regulatory progress, procedure volume, and software capability reinforce each other over time.

The size of the win is best expressed as a scenario, not a forecast. Remedy cites a market failure in which fewer than 3% of eligible stroke patients worldwide can access life-saving endovascular intervention in time, a company claim that should be treated cautiously but does capture the scale of the access problem being targeted [Remedy Robotics, retrieved 2026]. If the company were to secure regulatory clearance, become embedded in major hospital networks, and extend from neurovascular into broader vascular intervention, the resulting business could plausibly resemble a high-value strategic platform in robotic medtech rather than a niche device maker. Public materials here do not provide a clean external TAM benchmark or a directly comparable public peer that can be cited with confidence, so the most defensible formulation is narrower: if the "remote stroke hub standard" scenario plays out, Remedy could grow into a multi-asset platform of strategic value to large medtech acquirers or public-market investors focused on robotic intervention technology (scenario, not a forecast) [PR Newswire, November 2026] [Finsmes, November 2026].

Unconfirmed -- This section relies materially on company statements and funding coverage, with limited independent clinical corroboration for hospital collaboration, remote procedure, and market-access claims.

Sources

From the public record

  1. [Crunchbase, retrieved 2026] Remedy Robotics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/remedy-robotics

  2. [PR Newswire, November 2026] Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere | https://www.prnewswire.com/news-releases/remedy-robotics-raises-62-million-series-b-to-bring-life-saving-cardiovascular-intervention-to-patients-everywhere-302939871.html

  3. [Finsmes, November 2026] Remedy Robotics Raises $62M in Series B Funding | https://www.finsmes.com/2026/11/remedy-robotics-raises-62m-in-series-b-funding.html

  4. [Remedy Robotics, retrieved 2026] Remedy Robotics | AI-powered endovascular intervention | https://www.remedyrobotics.com/

  5. [Startup Daily, retrieved 2026] Expats remote surgery medtech scores $92 million Series B for stroke care | https://www.startupdaily.net/topic/funding/expats-remote-surgery-medtech-scores-92-million-series-b-for-stroke-care/

  6. [RocketReach, retrieved 2026] Jake Sganga profile | https://rocketreach.co/

  7. [Stanford Bio-X, retrieved 2026] Stanford Bio-X Bowes Fellowship | https://biox.stanford.edu/

  8. [HIT Consultant, November 2026] Remedy Robotics Raises $62 Million Series B | https://hitconsultant.net/2026/11/16/remedy-robotics-raises-62-million-series-b-dcvc-endovascular-stroke-robotics/

  9. [PitchBook, retrieved 2026] Remedy Robotics 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/481184-38

  10. [citybiz, retrieved 2026] Remedy Robotics Raises $62M Series B Led by DCVC to Advance AI-Powered Surgical Robotics | https://www.citybiz.co/article/933907/remedy-robotics-raises-62m-series-b-led-by-dcvc-to-advance-ai-powered-surgical-robotics/

Articles about Remedy Robotics

View on Startuply.vc